Moventig

RSS

naloxegol

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Moventig. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Moventig.

For practical information about using Moventig, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 09/12/2022

Authorisation details

Product details
Name
Moventig
Agency product number
EMEA/H/C/002810
Active substance
naloxegol oxalate
International non-proprietary name (INN) or common name
naloxegol
Therapeutic area (MeSH)
  • Constipation
  • Opioid-Related Disorders
Anatomical therapeutic chemical (ATC) code
A06AH03
Publication details
Marketing-authorisation holder
Kyowa Kirin Holdings B.V.
Revision
15
Date of issue of marketing authorisation valid throughout the European Union
07/12/2014
Contact address

Bloemlaan 2
2132NP Hoofddorp
The Netherlands

Product information

07/07/2022 Moventig - EMEA/H/C/002810 - II/0038

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Peripheral opioid receptor antagonists
  • Drugs for constipation

Therapeutic indication

Treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating